NASDAQ Stocks Adial Pharmaceuticals (NASDAQ: ADIL) Rallies After Validating Bio-marker For AD04 Phase 3 Trial Adial Pharmaceuticals, Inc (NASDAQ: ADIL) was one of the top gainers at the close of the week after is gained by 30.95% in Friday’s session. This followed the company’s announcement that, it had validated its genetic biomarker for the planned phase